Freedom To Do More

Bone pain imprisons your patients. Address the pain with tolerability that may not limit other treatment options. QUADRAMET^® delivers a short half-life radionuclide that targets multiple lesions with a single injection.

EFFECTIVE PAIN RELIEF

• 62% to 72% of patients had relief in the first 4 weeks after administration²
• Patients who respond to QUADRAMET may begin to experience pain relief in one week¹

Some patients have reported a transient increase in bone pain within 72 hours of injection (flare reaction) which is usually mild and self-limiting

SIGNIFICANT REDUCTION IN PAIN WITH QUADRAMET

Significant reduction in pain scores.^1,3

* Statistically significant difference in change from baseline in comparison to placebo group.

• Maximal pain relief generally occurs at 3 to 4 weeks after injection of QUADRAMET¹

REDUCTION IN OPIOID ANALGESIC CONSUMPTION IN TWO PIVOTAL TRIALS^2,3

Patients who experience a reduction in pain may be encouraged to decrease their use of opioid analgesics.

LONG-LASTING RELIEF – AND THE FREEDOM OF A SINGLE INJECTION

• 16-week duration of pain relief for patients who responded to a single injection of QUADRAMET at
  1.0 mCi/kg.²

Sustained relief with 1.0 mCi/kg QUADRAMET

Percentage of patients who had relief of pain according to a physician-completed global assessment. Graph adapted from Serafini et al.²

*Statistically significant difference from placebo during the first 4 weeks.²

FREEDOM TO REPEAT TREATMENT OF RECURRENT BONE PAIN

"The pain response after multiple administrations of [Quadramet] is similar to that after an initial administration both in terms of decrease in pain intensity scores and percentage of patients responding."⁴

Before QUADRAMET is administered, consideration should be given to the patient's current clinical and hematologic status and previous bone marrow response to myelosuppressive treatments.